COVID-19 Vaccines - Russia

  • Russia
  • The COVID-19 Vaccines market in Russia is expected to witness significant growth in the coming years.
  • By 2024, the projected revenue for this market is estimated to be US$0.00m.
  • Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2028) of US$0.00m, which will lead to a market volume of [globalrevenue_currentlayer_yeartoday_currentcountryvalue] by 2028.
  • In terms of global comparison, United States is projected to generate the highest revenue in the COVID-19 Vaccines market.
  • In 2024 alone, United States is expected to generate a revenue of US$1,832,000.00k.
  • Russia's COVID-19 vaccine market is dominated by Sputnik V, which has gained international recognition for its efficacy and has been widely adopted domestically.

Key regions: Japan, Italy, China, South Korea, Brazil

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Russia, like many other countries, is experiencing a surge in demand for COVID-19 vaccines. The market for COVID-19 vaccines in Russia is developing at a steady pace, driven by various factors such as customer preferences, local special circumstances, and underlying macroeconomic factors.

Customer preferences:
Russian customers are showing a strong preference for domestically produced vaccines, such as Sputnik V, which has been approved for use in Russia and in several other countries. This preference for domestic products is driven by a combination of national pride and concerns about vaccine safety and efficacy. Additionally, there is a growing demand for vaccines that can be stored and transported at normal refrigeration temperatures, which is an important consideration for a country as vast as Russia.

Trends in the market:
One trend that is emerging in the Russian market is the increasing availability of vaccines in pharmacies. This is a departure from the initial rollout of the vaccine, which was largely centralized and administered through government-run clinics. The availability of vaccines in pharmacies is making it easier for people to get vaccinated, which is helping to drive up vaccination rates. Additionally, there is a growing interest in booster shots, as people seek to maintain their immunity against the virus.

Local special circumstances:
Russia has a unique set of circumstances that are shaping the development of the COVID-19 vaccine market. For one, the country has a large population that is spread out across a vast geographic area. This presents logistical challenges for vaccine distribution and storage. Additionally, there is a high level of vaccine hesitancy among some segments of the population, which is slowing the pace of vaccination. Finally, the government has been actively promoting the use of domestically produced vaccines, which has helped to boost the market for these products.

Underlying macroeconomic factors:
The Russian economy has been hit hard by the COVID-19 pandemic, which has led to a decline in consumer spending and investment. However, the government has been investing heavily in the development and production of vaccines, which has helped to boost the market for these products. Additionally, the government has implemented a range of measures to support businesses and individuals during the pandemic, which has helped to mitigate the economic impact of the crisis. Overall, the COVID-19 vaccine market in Russia is developing in response to a complex set of factors, including customer preferences, local special circumstances, and underlying macroeconomic factors.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)